國藥科技股份(08156.HK)年度淨虧損大幅收窄至1.06億港元
格隆匯9月29日丨國藥科技股份(08156.HK)公佈年度業績,截至2021年6月30日止6個月,公司收益為7781.3萬港元,同比減少53.11%;公司股權持有人應占年度虧損為1.06億港元,同期則虧損為1.61億港元,基本每股虧損為2.47港仙。
收入減少乃由於疫情影響下電商生態系統有所變動,以及一項與線上平台之服務合約並無就提供"互聯網+"供應鏈服務獲得重續,且停止提供業務管理及顧問服務予國藥藥材的管理服務協議。
股權持有人應占虧損減少的主要原因為於2021年度就商譽作出減值虧損的影響少於2020年度,以及來自分佔聯營公司溢利的貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.